Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jan 21, 2022; 28(3): 310-331
Published online Jan 21, 2022. doi: 10.3748/wjg.v28.i3.310
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 The molecular pathways that regulate non-alcoholic fatty liver disease-related hepatocellular carcinoma along with their interactions are represented. Activation of downstream signaling pathways is indicated by full or dot lines whereas inhibition of them is indicated by blunted lines with a circular-shaped “X”. Bidirectional arrows highlight the interplay between distinct molecular pathways. Molecules acting as mediators of signaling paths are indicated over a full, dot or blunted line in a box along with their names. MicroRNAs that promote hepatocellular carcinoma development are collectively represented in the upper left of the figure while tumor suppressor microRNAs are represented in the lower left of the schema. Cas: Caspase; DCA: Deoxycholic acid; ER: Endoplasmic reticulum; FFAs: Free fatty acids; HCC: Hepatocellular carcinoma; HDAC8: Histone deacetylase 8; HSCs: Hepatic stellate cells; IGF: Insulin growth factor; IL-6: Interleukin-6; IRec: Insulin receptor; IRes: Insulin resistance; JNK: Jun-(N)-terminal kinase; KC: Kuppfer cell; lncRNAs: Long non-coding RNAs; LPS: Lipopolysaccharides; MAPK: Mitogen-activated protein kinase; PAMPs: Pathogen-associated molecular patterns; SASP: Senescence associated secretory phenotype; STAT3: Signal transducer and activator of transcription 3; TGF-B: Transforming growth factor-B; TLR: Toll-liκe receptor.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Proposed algorithm for hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease patients based on the latest guidelines. HCC: Hepatocellular carcinoma; NAFLD: Non-alcoholic fatty liver disease; US: Ultrasonography; AFP: Alpha-fetoprotein; CT: Computer tomography; MRI: Magnetic resonance imaging; BMI: Body mass index.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Proposed algorithm for hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease patients based on future perspectives. HCC: Hepatocellular carcinoma; NAFLD: Non-alcoholic fatty liver disease; PNPLA3: Patatin-like phospholipase domain-containing protein 3; MiRNAs: Micro-RNAs; lnc-RNAs: Long non-coding-RNAs; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; US: Ultrasonography; CT: Computer tomography; MRI: Magnetic resonance imaging; BMI: Body mass index.